CA
NZ
UK
AU
IND
US
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat bronchial asthma in children aged 6 to 11 years. The authorization applies to pediatric patients with severe …
GE HealthCare (Nasdaq:GEHC) has signed a multi-year agreement to supply over 300 CT (computed tomography) scanners to public hospitals under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program. The deployment will cover all 38 provinces, including urban and remote regions, and is expected to …
On December 16, 2025, shares of Pfizer Inc (NYSE:PFE), a global biopharmaceutical company, declined around 3.4% to close at USD 25.53, following the release of updated financial expectations for 2025 and guidance into 2026. The revised outlook includes a lower anticipated revenue figure for …
Quipt Home Medical (NASDAQ:QIPT) announced its quarterly financial results earlier this week. The company reported anearnings per shareloss of USD 0.08 for the quarter. This compared with a consensus estimate of a USD 0.03 profit, resulting in a miss of USD 0.11, according to …
Tilray Brands (NASDAQ:TLRY) experienced a 10% decline in Monday trading following heightened investor expectations over marijuana rescheduling. Late last week, several media reports suggested that President Donald Trump might sign an executive order (EO) directing the Justice Department to begin reclassifying the drug.
Nutriband Inc. (NASDAQ:NTRB) released its quarterly earnings results on Wednesday, with reported figures showing a narrower loss than analysts had anticipated. The announcement was followed by a slight increase in the company’s share price during U.S. trading on December 15, 2025, with the market …
Novo Nordisk (NYSE:NVO) recorded a gain of nearly 3% on December 12, 2025, to close at USD 50.29. The advance followed news of a legislative effort aimed at restricting the compounding of certain approved drugs, including GLP-1 treatments. The company is widely known for …
Dyne Therapeutics (NASDAQ:DYN) delivered an upbeat performance, standing out in a mixed biotech market. Shares advanced nearly 7% after Oppenheimer analyst Jay Olson upgraded the stock from perform to outperform and raised his price target from USD 11 to USD 40 — almost a …
Dyne Therapeutics (NASDAQ:DYN) saw its shares drop nearly 17%, after the biotech announced a substantial secondary stock offering. While it’s common for biotechnology companies to raise cash following encouraging clinical data, the size of Dyne’s new offering caught investors off guard. The company revealed …
Phreesia (NYSE:PHR) experienced a steep 23% decline, after releasing its fiscal third-quarter results. The reaction came as a surprise to many observers, given that the healthcare services technology company reported meaningful improvements across key performance metrics.Revenuefor the quarter rose 13%year over yearto slightly above …
Please wait processing your request...